(Q40499796)

21 September 2017

title

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers (English)

1 reference

L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-

21 September 2017

main subject

phase II clinical trial

0 references

Dolabella auricularia

1 reference

inferred from

reverse claim

1 reference

8

Everett E Vokes

1 reference

21 September 2017

James Lewis Abbruzzese

5

object named as

James L Abbruzzese

1 reference

21 September 2017

Hedy L Kindler

1

1 reference

21 September 2017

Peter K Tothy

2

1 reference

21 September 2017

Robert Wolff

3

1 reference

21 September 2017

Richard A McCormack

4

1 reference

21 September 2017

Sridhar Mani

6

1 reference

21 September 2017

Kurombi T Wade-Oliver

7

1 reference

21 September 2017

publication date

1 October 2005

1 reference

Investigational New Drugs

21 September 2017

published in

1 reference

21 September 2017

volume

23

1 reference

21 September 2017

issue

5

1 reference

21 September 2017

page(s)

489-493

1 reference

Review of gemcitabine in biliary tract carcinoma

21 September 2017

cites work

1 reference

12 December 2020

Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification

1 reference

12 December 2020

Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.

1 reference

12 December 2020

Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Carcinoma of the gallbladder

1 reference

12 December 2020

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma

1 reference

12 December 2020

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain

1 reference

12 December 2020

A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

1 reference

12 December 2020

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors

1 reference

12 December 2020

Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial

1 reference

12 December 2020

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

1 reference

12 December 2020

Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.

1 reference

12 December 2020

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay

1 reference

12 December 2020

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer

1 reference

12 December 2020

Systemic therapy for advanced hepatocellular carcinoma: a review.

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study

1 reference

12 December 2020

10.1007/S10637-005-2909-X

Identifiers

DOI

1 reference

Dimensions Publication ID

21 September 2017

1049005503

0 references

1 reference